Psychedelic research institution MAPSdosed a $100 million Series A for MDMA-assisted therapy.
Why it matters: Confronted with an ongoing mental health crisis worsened by a provider shortage, stakeholders like government agencies, VC, and research institutions are warming to psychedelics' therapeutic potential.